The response to erlotinib third-line treatment in bronchioalveolar carcinoma in the absence of EGFR expression P. Krawczyk, W. Remiszewski, B. Gryglicka, M. Pelak, E. Czekajska-Chehab, E. Warda, K. Wojas-Krawczyk, O. Jankowska, J. Milanowski (Lublin, Poland)
Source: Annual Congress 2009 - Treatment of lung cancer
Session: Treatment of lung cancer Session type: Thematic Poster Session Number: 2642
Disease area: Thoracic oncologyAbstract Bronchoalveolar carcinoma is "minimal invasive" form of adenocarcinoma, which spreads along the intra alveolar septum and is weakly associated with cigarette smoking. The EGFR tyrosine kinase inhibitors (TKIs), e.g. erlotinib, have proven effective in some patients with advanced NSCLC previously treated and progressed on chemotherapy. We reported the rare case of adenocarcinoma with BAC feature evidently responding to erlotinib in the absence of EGFR protein expression on cancer cells. However, increased EGFR gene copy number in cancer cells was detected (FISH).
Unusually, since 8 months we have observed partial remission in patient with multiple distant metastases after failure of first and second line chemotherapy. The regression of multiple cancer micronoduli in the lung and reduction of metastases at mediastinal lymph nodes, liver and brain as well as stabilisation of bone metastases were noted.
Conclusion: tyrosine kinase inhibitors may have important role in BAC treatment especially in non-smokers with increased EGFR gene copy number in tumour, even in the absence of EGFR protein expression.Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Krawczyk, W. Remiszewski, B. Gryglicka, M. Pelak, E. Czekajska-Chehab, E. Warda, K. Wojas-Krawczyk, O. Jankowska, J. Milanowski (Lublin, Poland). The response to erlotinib third-line treatment in bronchioalveolar carcinoma in the absence of EGFR expression. Eur Respir J 2009; 34: Suppl. 53, 2642
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: